Publications scientifiques sur le VIH
Establishing normative ranges and standard deviation score (SDS) calculations for serum IGF-1 in adults with HIV: implications for tesamorelin (EGRIFTA) therapy.
2011
Cohen P, Soulban G, Zoltowska M, et al.
"Poster presented at: International Symposium on IGF-1, GH, and Ghrelin/GHS; March 4-6, 2011; Orlando, Florida, USA. "
Effects of tesamorelin, a growth hormone-releasing factor (GRF) analogue, on bone turnover markers in HIV-infected patients with excess abdominal fat.
2011
Mamputu J-C, Soulban G, Falutz J, et al.
Poster #834 presented at: Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, Massachusetts, USA.
Metabolic risk factors in responders to tesamorelin, a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with excess abdominal fat [abstract].
2011
Antiviral Therapy
Falutz J, Assaad H, Marsolais C, et al.
16(suppl 2): A29. Proceedings of the 13th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV.
Metabolic risk factors in responders to tesamorelin, a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with excess abdominal fat.
2011
Falutz J, Assaad H, Marsolais C, et al.
"Poster presented at: 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV; July 14-16, 2011; Rome, Italy. "
Significant improvement in belly image parameters and health-related quality of life in responders vs. non-responders to tesamorelin, a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with excess abdominal fat [abstract].
2011
Turner R, Potvin D, Mamputu J-C, et al.
13th European AIDS Conference; October 12-15, 2011; Belgrade, Serbia.